Howard Capital Management LLC Acquires 2,392 Shares of IDEXX Laboratories, Inc. $IDXX

Howard Capital Management LLC bought a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the 3rd quarter, HoldingsChannel.com reports. The institutional investor bought 2,392 shares of the company’s stock, valued at approximately $1,249,000.

Other institutional investors have also recently made changes to their positions in the company. V Square Quantitative Management LLC increased its holdings in IDEXX Laboratories by 4.9% in the 3rd quarter. V Square Quantitative Management LLC now owns 2,171 shares of the company’s stock worth $1,134,000 after acquiring an additional 102 shares during the last quarter. Assenagon Asset Management S.A. raised its stake in IDEXX Laboratories by 39.9% in the 3rd quarter. Assenagon Asset Management S.A. now owns 256,362 shares of the company’s stock valued at $133,870,000 after acquiring an additional 73,129 shares during the period. Fort Washington Investment Advisors Inc. OH bought a new stake in IDEXX Laboratories in the 3rd quarter valued at about $538,000. Birchbrook Inc. lifted its holdings in IDEXX Laboratories by 0.6% during the third quarter. Birchbrook Inc. now owns 4,505 shares of the company’s stock valued at $2,352,000 after purchasing an additional 28 shares during the last quarter. Finally, Signal Advisors Wealth LLC purchased a new stake in IDEXX Laboratories during the third quarter valued at about $265,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Insider Buying and Selling

In other IDEXX Laboratories news, Director Lawrence D. Kingsley sold 2,203 shares of the firm’s stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $532.08, for a total value of $1,172,172.24. Following the completion of the transaction, the director owned 9,568 shares in the company, valued at $5,090,941.44. This trade represents a 18.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.79% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

IDXX has been the subject of a number of research reports. JPMorgan Chase & Co. cut their target price on shares of IDEXX Laboratories from $775.00 to $750.00 and set an “overweight” rating for the company in a research report on Friday. Wall Street Zen downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. KeyCorp initiated coverage on shares of IDEXX Laboratories in a research report on Monday, October 12th. They issued a “sector weight” rating on the stock. Barclays dropped their price target on shares of IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 11th. Finally, UBS Group upped their price target on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the company a “neutral” rating in a research note on Wednesday, August 5th. Seven investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $744.09.

IDEXX Laboratories Price Performance

IDEXX Laboratories stock opened at $560.36 on Friday. IDEXX Laboratories, Inc. has a one year low of $500.61 and a one year high of $769.98. The business has a fifty day moving average price of $534.22 and a 200-day moving average price of $551.84. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.17 and a quick ratio of 0.87. The firm has a market capitalization of $44.15 billion, a P/E ratio of 39.41, a PEG ratio of 2.99 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share for the quarter, beating the consensus estimate of $3.94 by $0.33. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%. The company had revenue of $1.22 billion during the quarter, compared to analysts’ expectations of $1.20 billion. During the same period in the previous year, the business earned $3.50 earnings per share. The firm’s quarterly revenue was up 9.7% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. As a group, equities research analysts forecast that IDEXX Laboratories, Inc. will post 14.81 EPS for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology and water-testing products and services. The company primarily serves the companion animal veterinary market, helping veterinary practices diagnose and manage diseases through laboratory testing, in-house analyzers, diagnostic kits, imaging systems, software and related consumables.

IDEXX’s companion animal offerings include its IDEXX Reference Laboratories, IDEXX VetLab instruments and software, SNAP rapid tests, and practice-management and data solutions.